Hospital
Clhg-Avoyelles, LLC
Clhg-Avoyelles, LLC was paid $4.59M by Medicaid between Jan 2018 and Dec 2024, across 87 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
33Billing provider infoCLHG-AVOYELLES, LLC
MARKSVILLE, LA 71351
MARKSVILLE, LA 71351
33aNPI1053358176assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.59M
24GClaims156,246
24DCodes billed87
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#52 of 96
Median peer was paid$5.17M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,370 | $420K | |
| 2019 | 20,300 | $363K | |
| 2020 | 15,747 | $282K | |
| 2021 | 22,441 | $662K | |
| 2022 | 24,449 | $801K | |
| 2023 | 33,944 | $1.23M | |
| 2024incomplete | 19,995 | $841K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 20,067 | 17,981 | $1.44M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 11,971 | 10,262 | $1.38M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.5% | 2,671 | 2,227 | $344K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.3% | 305 | 270 | $195K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 24,687 | 19,908 | $122K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 1,719 | 1,578 | $89K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.9% | 2,007 | 1,561 | $88K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 6,124 | 5,035 | $88K |
| G0378 | Hospital observation service, per hour | 1.8% | 1,303 | 1,015 | $83K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 14,672 | 11,463 | $73K |
| 80050 | General health panel | 1.4% | 1,632 | 1,479 | $65K |
| 80053 | Comprehensive metabolic panel | 1.4% | 7,967 | 7,077 | $65K |
75 more codes
| 80061 | Lipid panel | 1.4% | 6,154 | $64K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.2% | 2,315 | $54K |
| 94762 | <1% | 1,911 | $41K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 505 | $39K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 807 | $29K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,427 | $27K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,008 | $24K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 79 | $21K |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,271 | $19K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 59 | $18K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,658 | $17K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 127 | $16K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,444 | $16K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 346 | $15K |
| 87276 | <1% | 1,578 | $15K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,293 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,984 | $14K |
| 81025 | <1% | 1,857 | $13K | |
| 81003 | <1% | 9,636 | $12K | |
| 87275 | <1% | 842 | $10K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 719 | $10K |
| 93041 | <1% | 689 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 589 | $7K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 34 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 413 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 516 | $5K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 26 | $3K |
| 87070 | <1% | 441 | $3K | |
| 87430 | <1% | 212 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 159 | $3K |
| 82552 | <1% | 344 | $3K | |
| 86140 | <1% | 447 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 95 | $2K |
| 87110 | <1% | 111 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 80 | $2K |
| 84484 | <1% | 260 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,470 | $1K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 21 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 113 | $1K |
| 94664 | <1% | 38 | $1K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 131 | $1K |
| 72050 | <1% | 13 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,812 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 222 | $1K |
| 80076 | <1% | 215 | $1K | |
| 85652 | <1% | 455 | $975.27 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 295 | $956.74 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,454 | $865.58 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16 | $825.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 33 | $821.35 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 17 | $532.86 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 46 | $486.50 |
| 84134 | <1% | 83 | $447.03 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 13 | $424.59 |
| 82150 | <1% | 89 | $351.22 | |
| 82607 | <1% | 28 | $349.41 | |
| 82746 | <1% | 29 | $340.60 | |
| 82043 | <1% | 76 | $317.32 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 108 | $225.58 |
| 99406 | <1% | 17 | $221.52 | |
| 94760 | <1% | 59 | $210.25 | |
| 87899 | <1% | 16 | $208.91 | |
| J3490 | Unclassified drugs | <1% | 80 | $191.30 |
| 84439 | <1% | 18 | $135.30 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 28 | $107.82 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 147 | $82.21 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 203 | $76.24 |
| 83735 | <1% | 14 | $75.73 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 154 | $57.43 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 31 | $55.69 |
| 85651 | <1% | 15 | $55.22 | |
| 83880 | <1% | 15 | $39.26 | |
| 36000 | <1% | 15 | $29.56 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 72 | $24.76 |
| 86901 | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRYANT, MONICA (CFO)